{"slideshow_credits": null, "snippet": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "abstract": "Valeant Pharmaceuticals says it is being investigated by Securities and Exchange Commission; has come under scrutiny for its high drug prices and dealings with mail-order pharmacy.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS"}, "web_url": "http://www.nytimes.com/2016/03/01/business/valeant-pharmaceuticals-is-under-sec-investigation.html", "lead_paragraph": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "headline": {"main": "Valeant Pharmaceuticals Is Under S.E.C. Investigation", "print_headline": "<span data-tag=\"tight__4\">After Tumultuous Day for Valeant, Latest Blow Is an S.E.C. Investigation</span>"}, "_id": "56d4c6f438f0d811294b816c", "word_count": "641", "multimedia": [{"height": 126, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-03-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Securities and Exchange Commission", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}